Elevating the Treatment of Cancer

The Summit Is Clear

once you pass through the clouds

We believe that every patient deserves to know what is driving the growth of their cancer and how best to treat it


Elevating precision medicine to the forefront of every cancer treatment journey

Our vision is a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.

Together with our drug and diagnostic developer peers, we work to enable a personalized treatment plan for each individual patient with cancer.

Our Focus

Genomic testing illuminates the path

Your tumor has a genomic fingerprint that may help your physician map the best path to overcoming it.

We advocate for every patient to get their tumor genomically tested. Only through testing can we give patients their best chance at improved outcomes.

Learn More About Genomic Testing Patient-Doctor Discussion Guide

Blazing the trail to make genomic test results actionable

We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer ⏤ no matter how rare.

Our lead drug candidate, seribantumab, inhibits tumor growth driven by NRG1 gene fusions. Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion.

Learn More About CRESTONE

Introducing Elevation Oncology


The time is now to elevate how cancer is treated. It is critical that each patient has access to the right physicians, the right tests, and the right therapeutics to treat their individual tumor based on its unique profile. All of us at Elevation Oncology are excited to work with our peers under one united goal – to create better outcomes for patients with cancer. I look forward to embarking on this journey together with you.

Get to know us 

JULY 21, 2020

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations